Autopsy report · NCT05493618

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study Drug Unavailability”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 1, Phase 2
Sponsor: Hackensack Meridian Health
Sponsor type: University, hospital or other
Conditions: Multiple Myeloma, Refractory
Interventions: Pembrolizumab; Belantamab mafodotin; Dexamethasone
Participants: 0
Sites: 3
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.